Sources | Names Used |
---|---|
CTRPv2 | sirolimus:bortezomib (250:1 mol/mol) |
PharmacoGx | sirolimus:bortezomib (250:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ACSL3 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0009 |
mRNA | ACSS2 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.01 |
mRNA | ACTN1 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.0001 |
mRNA | ACTN3 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |
mRNA | ACTN4 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0001 |
mRNA | AD000671.6 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.008 |
mRNA | ADAR | CTRPv2 | pan-cancer | AAC | 0.19 | 4e-08 |
mRNA | ADAT1 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
mRNA | ADAT3 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.003 |
mRNA | ADGRE2 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.002 |